DEVELOPMENT AND STUDY OF MITOXANTRONE ANTI-CD5-IMMUNOLIPOSOME IN VITRO


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Immunoliposomal Mitoxantrone against CD5+ T-cell limphoproliferative diseases was developed. Liposomal model with lipid proportion PhCh: Chol: mPEG2000-DSPE: pNP-PEG3000-lipid 11: 9: 0,95: 0,05 was used for immu-noliposome development. We used gel-filtration to remove free Mitoxantrone and unconjugated monoclonal antibody from immunoloposomal construction. One liposome was conjugated with ~16 antibody molecules. Immunoliposomes linked with 80% of antigen+ cells. Immunoloposomal Mitoxantrone killed antigen+ target cells in MTT-assay.

About the authors

A. A. Matyushin

First Moscow State Medical University

Author for correspondence.
Email: foralan79@mail.ru
Russian Federation

O. V. Khugaeva

First Moscow State Medical University

Russian Federation

M. A. Baryshnikova

FSBI "N.N. Blokhin Russian Cancer Research Center"

Russian Federation

A. O. Raykov

FSBI "N.N. Blokhin Russian Cancer Research Center"

Russian Federation

A. Yu. Baryshnikov

FSBI "N.N. Blokhin Russian Cancer Research Center"

Russian Federation

References

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c)


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС77-53039 от  04.03.2013.